|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
100,490,000 |
Market
Cap: |
7.47(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$9.24 - $94.5 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders. Co.'s primary clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRss). Co. is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRss for X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
45,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$111,195 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
459,079 |
504,079 |
605,079 |
1,266,845 |
Total Sell Value |
$12,216,534 |
$13,176,534 |
$15,570,784 |
$27,492,457 |
Total People Sold |
2 |
3 |
5 |
6 |
Total Sell Transactions |
5 |
7 |
10 |
21 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Mancini Marianna |
Chief Operating Officer |
|
2024-03-27 |
4 |
D |
$83.34 |
$1,384,277 |
D/D |
(16,610) |
363,565 |
|
- |
|
Mancini Marianna |
Chief Operating Officer |
|
2024-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
31,667 |
380,175 |
|
- |
|
Lian Brian |
President & CEO |
|
2024-03-27 |
4 |
D |
$83.34 |
$12,830,026 |
D/D |
(153,948) |
2,266,453 |
|
- |
|
Lian Brian |
President & CEO |
|
2024-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
221,667 |
2,420,401 |
|
- |
|
Zante Greg |
Chief Financial Officer |
|
2024-03-27 |
4 |
D |
$83.34 |
$1,384,277 |
D/D |
(16,610) |
207,361 |
|
- |
|
Zante Greg |
Chief Financial Officer |
|
2024-03-27 |
4 |
A |
$0.00 |
$0 |
D/D |
31,667 |
223,971 |
|
- |
|
Lian Brian |
President & CEO |
|
2024-03-01 |
4 |
D |
$85.22 |
$13,875,094 |
D/D |
(162,815) |
2,198,734 |
|
- |
|
Lian Brian |
President & CEO |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
221,667 |
2,361,549 |
|
- |
|
Mancini Marianna |
Chief Operating Officer |
|
2024-03-01 |
4 |
D |
$85.22 |
$1,445,161 |
D/D |
(16,958) |
348,508 |
|
- |
|
Mancini Marianna |
Chief Operating Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
31,667 |
365,466 |
|
- |
|
Zante Greg |
Chief Financial Officer |
|
2024-03-01 |
4 |
D |
$85.22 |
$1,712,325 |
D/D |
(20,093) |
192,304 |
|
- |
|
Zante Greg |
Chief Financial Officer |
|
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
31,667 |
212,397 |
|
- |
|
Lian Brian |
President & CEO |
|
2024-02-09 |
4 |
AS |
$29.90 |
$1,345,500 |
D/D |
(45,000) |
2,139,882 |
|
143% |
|
Lian Brian |
President & CEO |
|
2024-02-08 |
4 |
AS |
$25.75 |
$7,230,784 |
D/D |
(269,079) |
2,184,882 |
|
157% |
|
Lian Brian |
President & CEO |
|
2024-02-08 |
4 |
OE |
$1.23 |
$711,367 |
D/D |
189,079 |
2,404,882 |
|
- |
|
Rouan Sarah Kathryn |
Director |
|
2024-02-08 |
4 |
AS |
$28.05 |
$701,250 |
D/D |
(25,000) |
0 |
|
157% |
|
Rouan Sarah Kathryn |
Director |
|
2024-02-08 |
4 |
OE |
$8.32 |
$208,000 |
D/D |
25,000 |
25,000 |
|
- |
|
Lian Brian |
President & CEO |
|
2024-01-31 |
4 |
AS |
$24.45 |
$2,100,750 |
D/D |
(85,000) |
2,264,882 |
|
208% |
|
Lian Brian |
President & CEO |
|
2024-01-31 |
4 |
OE |
$1.23 |
$104,550 |
D/D |
85,000 |
2,349,882 |
|
- |
|
Lian Brian |
President & CEO |
|
2024-01-30 |
4 |
AS |
$23.95 |
$838,250 |
D/D |
(35,000) |
2,264,882 |
|
212% |
|
Lian Brian |
President & CEO |
|
2024-01-30 |
4 |
OE |
$1.23 |
$43,050 |
D/D |
35,000 |
2,299,882 |
|
- |
|
Rouan Sarah Kathryn |
Director |
|
2024-01-19 |
4 |
AS |
$23.05 |
$691,500 |
D/D |
(30,000) |
0 |
|
241% |
|
Rouan Sarah Kathryn |
Director |
|
2024-01-19 |
4 |
OE |
$8.32 |
$249,600 |
D/D |
30,000 |
30,000 |
|
- |
|
Zante Greg |
Chief Financial Officer |
|
2024-01-04 |
4 |
S |
$17.90 |
$268,500 |
D/D |
(15,000) |
180,730 |
|
-271% |
|
Zante Greg |
Chief Financial Officer |
|
2024-01-04 |
4 |
D |
$18.58 |
$257,742 |
D/D |
(13,872) |
195,730 |
|
- |
|
162 Records found
|
|
Page 1 of 7 |
|
|